DAFTAR PUSTAKA

Alifieris, C., Trafalis, D.T., 2015. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol. Ther. 152, 63–82. https://doi.org/10.1016/j.pharmthera.2015.05.005

American Brain Tumor Association. (2017). Glioblastoma and Malignant Astrocytoma. [Internet]. Available from: http://www.abta.org/secure/glioblastoma-brochure.pdf.

Bell E. H., Zhang P., Fisher B. J., et al. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018;4(10):1405-1409. doi:10.1001/jamaoncol.2018.1977

Binabaj, M. M., Bahrami, A., ShahidSales, S., Joodi, M., Joudi Mashhad, M., Hassanian, S. M., Anvari, K., & Avan, A. (2018). The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Journal of cellular physiology, 233(1), 378–386. https://doi.org/10.1002/jcp.25896

Combs SE, Rieken S, Wick W, et al. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. Radiat Oncol. 2011;6:115. Published 2011 Sep 13. doi:10.1186/1748-717X-6-115

Diwanji, T. P., Engelman, A., Snider, J. W., & Mohindra, P. (2017). Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolescent health, medicine and therapeutics, 8, 99–113. https://doi.org/10.2147/AHMT.S53391

Florian I.S., et al. (2013) Risk factors for gliomas. An extensive review, Romanian Neurosurgery, XX 1, 5-21. DOI: 10.2478/v10282-012-0016-z.

Franceschi E., Tosoni A., Minichillo S., et al. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. World Neurosurgery, 2018-04-01, 112, e342-e347.

Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013; 31:4085-91.

Gittleman H., Lim D., Kattan M.W., Chakravarti A., Gilbert M.R., Lassman A.B., et. al.: An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol 2017; 19: pp. 669-677.

Gittleman H, Ostrom QT, Stetson LC, et al. Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. Neurooncol Pract. 2019;6(6):451-462. doi:10.1093/nop/npz019

Håvik AB, Brandal P, Honne H, et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med. 2012;10:36. Published 2012 Mar 6. doi:10.1186/1479-5876-10-36

Hofer, S., Rushing, E., Preusser, M., Marosi, C. (2014). Molecular biology of high-grade gliomas: what should the clinician know? Chin. J. Cancer 33, 4–7. https://doi.org/10.5732/cjc.013.10218

Jovanović N, Mitrović T, Cvetković VJ, et al. The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma. Medicina (Kaunas). 2019;55(2):34. Published 2019 Feb 1. doi:10.3390/medicina55020034

July J, Patricia D, Gunawan PY, et al. Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment. Pan Afr Med J. 2020;36:309. Published 2020 Aug 20. doi:10.11604/pamj.2020.36.309.24831

Lakomy R, Sana J, Hankeova S, et al. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. 2011 Dec;102(12):2186-90.

Lapointe, S., Perry, A., & Butowski, N. A. (2018). Primary brain tumours in adults. Lancet (London, England), 392(10145), 432–446. https://doi.org/10.1016/S0140-6736(18)30990-5

Liu Y, Scheurer ME, El-Zein R, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):204-14.

Louis, D. N. et al. (2016). 'The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary', Acta Neuropathologica. Springer Berlin Heidelberg, 131(6), pp. 803–820. doi: 10.1007/s00401-016-1545-1.

Malueka RG, Dwianingsih EK, Bayuangga HF, et al. Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population. Asian Pac J Cancer Prev. 2020;21(8):2287-2295. Published 2020 Aug 1. doi:10.31557/APJCP.2020.21.8.2287

Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol; Published 5 September 2018. doi: 10.1093/neuonc/noy132.

Mesfin FB, Al-Dhahir MA. Gliomas. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441874/

Michaud DS, Gallo V, Schlehofer B, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2562-9.

Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005 Jan;109(1):93-108.

Pandith AA, Qasim I, Baba SM, et al. Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma. Future Sci OA. 2020;7(3):FSO663. Published 2020 Dec 9. doi:10.2144/fsoa-2020-0057

Qi Z-Y, Shao C, Zhang X, Hui G-Z, Wang Z (2013) Exogenous and Endogenous Hormones in Relation to Glioma in Women: A Meta-analysis of 11 Case-Control Studies. PLoS ONE 8(7): e68695. https://doi.org/10.1371/journal.pone.0068695

Quinn T Ostrom, Nirav Patil, Gino Cioffi, et al. (2020) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology, Volume 22, Issue Supplement_1, October 2020, Pages iv1–iv96. https://doi.org/10.1093/neuonc/noaa200

Schiffgens S, Wilkens L, Brandes AA, et al. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in

glioblastoma. Oncotarget. 2016;7(34):55169-55180. doi:10.18632/oncotarget.10465

Shinojima N., et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg. 2004;101:219–26.

Sippl C., Urbschat S., Kim Y.J., Senger S., Oertel J., Ketter R.. Promoter methylation of RB1, P15, P16, and MGMT and their impact on the clinical course of pilocytic astrocytomas. Oncol Lett. 2018;15(2):1600-1606. doi:10.3892/ol.2017.7490

Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-66.

Sun T., Warrington N.M., Luo J., Brooks M.D., Dahiya S., Snyder S.C., et. al.: Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. J Clin Invest 2014; 124: pp. 4123-4133.

Toffolatti L., Scquizzato E., Cavallin S., et al. (2014). MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. Virchows Archiv, 465(5), 579–586. doi:10.1007/s00428-014-1622-6

Verger E., Valduvieco I., Caral L., et al. Does gender matter in glioblastoma? Clin Transl Oncol. 2011 Oct;13(10):737-41.

Wang P.F., Liu N., Song H.W., et al. IDH-1R132H mutation status in diffuse glioma patients: implications for classification. Oncotarget. 2016;7(21):31393-31400. doi:10.18632/oncotarget.8918

Wesseling P., Capper D. (2018). WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150. doi: 10.1111/nan.12432.

Whitmire P., Rickertsen C.R., Hawkins-Daarud A, et al. Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients. BMC Cancer. 2020;20(1):447. Published 2020 May 19. doi:10.1186/s12885-020-06816-2

Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014). MGMT testing--the challenges for biomarker-based glioma treatment. *Nature reviews. Neurology*, *10*(7), 372–385. https://doi.org/10.1038/nrneurol.2014.100

Yan W., Zhang W., You G., et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One. 2012;7(1):e30339. doi:10.1371/journal.pone.0030339

Yang P., Zhang W., Wang Y., et al. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget. 2015;6(38):40896-40906. doi:10.18632/oncotarget.5683

Yoshioka M., Matsutani T., Hara A., et al. Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma. Oncotarget. 2018;9(45):27728-27735. Published 2018 Jun 12. doi:10.18632/oncotarget.25543

Zhou K, Hu D, Lu J, Fan W, Liu H, Chen H, Chen G, Wei Q, Du G, Mao Y, Lu D, Zhou L. A genetic variant in the APE1/Ref-1 gene promoter -141T/G may modulate risk of glioblastoma in a Chinese Han population. BMC Cancer. 2011 Mar 23;11:104.